Biomarin Pharmaceutical Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Good afternoon, everyone. Thank you for joining us at the Jefferies Gene Therapy Summit. I have the pleasure of hosting Hank from BioMarin, the Head of BioMarin's R&D engine, and I really appreciate him taking the time to join with us, especially right after earnings which is always kind of a crazy time. So thanks so much, Hank.
Pleasure.
Questions & Answers
Now -- and by the way, I'm Akash Tewari, a senior analyst covering biotech at Jefferies. So because it's a Gene Therapy Summit, I think it's only fair that let's start off by talking a little bit about vosoritide. But like I think obviously, there's -- you have 2 very critical FDA approval decisions, one on ROCTAVIAN, one on VOXZOGO.
I think on the call yesterday, a question that I feel like we were honing in on and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
